StockNews.AI
SNN
StockNews.AI
166 days

New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty

1. Smith+Nephew’s OXINIUM shows a 94.1% survivorship rate for hip implants. 2. Four registries confirm OXINIUM reduces revision surgery risk by 35%. 3. Professor Walter highlights significant reductions in revision failures. 4. The manufacturing process enhances OXINIUM's durability and resistance. 5. Superior evidence strengthens market position among orthopedic implants.

13m saved
Insight
Article

FAQ

Why Bullish?

The positive report on OXINIUM's performance enhances Smith+Nephew's competitive position, suggesting potential sales growth. Historical performance data, like after the introduction of innovative products, typically reflects price appreciation.

How important is it?

The strong data backing OXINIUM positions SNN favorably within the competitive landscape. This could drive sales, influence investor sentiment, and elevate the stock's valuation.

Why Long Term?

Sustained high performance metrics reinforce market confidence over time. Similar cases show that consistent product performance leads to long-term investor interest and stock growth.

Related Companies

ZBHSYKMDT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew’s proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1 The report on 20-year outcomes corroborates similar findings and peer-reviewed publications from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR).2 Whitehouse et al. found that hip implants combining delta ceramic or OXINIUM (Oxidized Zirconium) heads with XLPE (highly cross-linked polyethylene) liners or cups had the lowest risk of needing revision surgery over a 15-year period.3  Four registries in total - including the Italian Registry (RIPO; Register of Orthopaedic Prosthetic Implants) and the Dutch Arthroplasty Register (LROI) - have now demonstrated that OXINIUM/XLPE had a 35% lower risk of revision at 10-years versus other modular acetabular implants1-5 These findings offer valuable guidance for surgeons and patients in selecting the most reliable implant materials for long-term outcomes. “When I started in practice more than 20 years ago bearing wear was the leading cause of failure of hip replacements,” said Prof. Bill Walter of The University of Sydney and Royal North Shore Hospital. “We used to see osteolysis as the main reason for revision. The AOANJRR now shows that bearing wear has been virtually eliminated as a cause of failure. The bearing combination of OXINIUM on highly cross-linked polyethylene leads the pack with revision rates at 20 years significantly lower than even metal on XLPE.”  Through a unique manufacturing process, the OXINIUM alloy becomes a ceramicised metal - a true material transformation - rather than an applied coating.6 It is this material transformation that provides OXINIUM with its ground-breaking performance benefits which include: Unrivalled Material Science: The durability of metal, the wear resistance of ceramic and corrosion resistance better than both metal and ceramic.6-16Differentiated Composition: Virtually no nickel, cobalt and chromium,16 with a 30x reduction in pro-inflammatory markers for OXINIUM.*17  As such, OXINIUM implants do not require declaration of the presence of CMR (carcinogenic, mutagenic, reprotoxic) substances on the labeling. “Registries throughout the world have highlighted the performance of OXINIUM for total hip arthroplasty. The AOANJRR report showing 20-year outcomes provides powerful evidence for payers, hospitals, surgeons, and patients of our truly differentiated and proven technology,” said Craig Gaffin, President of Global Orthopaedics at Smith+Nephew. “OXINIUM/XLPE continues to demonstrate superior revision rates across multiple global joint replacement registries.” To learn more about Smith+Nephew’s OXINIUM Technology and hip reconstruction portfolio, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego March 11-13, 2025 or visit https://www.smith-nephew.com/en-us/health-care-professionals/products/orthopaedics/oxinium.  - ends – Media Enquiries Dave Snyder          +1 (978) 749-1440  Smith+Nephew      david.snyder@smith-nephew.com *     ASTM International Standard Specification for Wrought Zirconium-2.5 Niobium Alloy for Surgical Implant Applications (UNS R60901) Designation: F 2384 – 10. References Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report Adelaide; AOA, 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed December 11, 2024National Joint Registry for England, Wales and Northern Ireland: 21st Annual Report. 2024. Available at: NJR 21st Annual Report 2024_Hips.pdf. Accessed January 06, 2025.Whitehouse MR, Patel R, French JMR, et al. The association of bearing surface materials with the risk of revision following primary total hip replacement: A cohort analysis of 1,026,481 hip replacements from the National Joint Registry. PLoS Med 2024;21(11): e1004478. Peters RM, Van Steenbergen LN, Stevens M, Rijk PC, Bulstra SK, Zijlstra WP. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthop. 2018:89;163–169. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901513/. Accessed November 9, 2023.Atrey A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.Hunter G, Dickinson J, Herb B, et al. Creation of oxidized zirconium orthopaedic implants. Journal of ASTM International. 2005;2:1-14.Long M, Riester L, Hunter G. Nano-hardness Measurements of Oxidized Zr-2.5Nb and Various Orthopaedic Materials. Abstract presented at: 24th Annual Meeting of the Society for Biomaterials. April 22-26, 1998, San Diego, California. Parikh A, Hill P, Hines G, Pawar V. Wear of conventional and highly crosslinked polyethylene liners during simulated fast walking/jogging. Poster presented at: Orthopaedic Research Society Annual Meeting; 2009; Las Vegas; NV.Parikh A, Hill P, Pawar V, Sprague J. Long-term Simulator Wear Performance of an Advanced Bearing Technology for THA. Poster presented at: 2013 Annual Meeting of the Orthopaedic Research Society. Poster no. 1028.Papannagari R, Hines G, Sprague J, Morrison M. Long-term wear performance of an advanced bearing technology for TKA. Poster presented at: Orthopaedic Research Society Annual Meeting; 2011; Long Beach, CA.Smith+Nephew 2010. OR-10-155. Aldinger P, Williams T, Woodard E. Accelerated fretting corrosion testing of zirconia toughened alumina composite ceramic and a new composition of ceramicised metal femoral heads. Poster presented at: Orthopaedic Research Society Annual Meeting; 2017; San Diego, CA.Smith+Nephew 2016. OR-16-127. 2005 ASM International Engineering Materials Achievement Award. Dalal A, Pawar V, McAllister K, Weaver C, Hallab NJ. Orthopedic implant cobalt-alloy particles produce greater toxicity and inflammatory cytokines than titanium alloy and zirconium alloy-based particles in vitro, in human osteoblasts, fibroblasts, and macrophages. J Biomed Mater Res Part A. 2012;100A:2147-2158. ASTM F2384-24 (May 2024). Standard specification for wrought zirconium-2.5niobium alloy for surgical implant applications (UNS R60901). Available at: https://www.astm.org/f2384-10r16.html. Accessed February 27, 2025Hallab NJ, McAllister K, Jacobs JJ, and Pawar, V. Zirconium-Alloy and Zirconium-Oxide Particles Produce less Toxicity and Inflammatory Cytokines than Cobalt-Alloy and Titanium-Alloy Particles In Vitro, in Human Osteoblasts, Fibroblasts and Macrophages. 2012 Annual Meeting of the Orthopaedic Research Society. Poster no. 0971. About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Related News